ClinicalTrials.gg
Not yet recruitingNCT06704022Updated Aug 11, 2025

Assessing Gut Microbiome Changes Before and After an Oral Nutritional Supplement Intake Using the SIMBA Capsule in Diabetic Participants

A Phase 1 interventional study of Oral nutritional supplement in Type 2 Diabetes, sponsored by Nimble Science Ltd.. Not yet recruiting at 1 site in Canada. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Nimble Science Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 756 studies in Diabetes Mellitus, Type 2 with a site in Canada — 81 open to participants now, 112 under way, 25 of them phase 3. Diabetes Mellitus, Type 2 · Canada.

Planned enrollment
565th of 673
30 · median 227
Started
2025
with 23 others
Phase 1
23 of 756
4 open now
Primary completion
2026-08
later than 32 of 111 live
Registered
698th of 756
by date

Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada, this one is the 565th largest by planned enrollment of the 673 interventional ones that give a count, is one of 24 that started in 2025, is one of 23 in phase 1, reaches primary completion later than 32 of the 111 other live ones, and was the 698th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

81 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 756 studies in Diabetes Mellitus, Type 2 with a site in Canada, or all of them as a file.
02

Study summary

This is a single-arm interventional clinical study, the primary objective is to assess the changes in the small intestinal (SI) metagenomic profile of in diabetic participants from baseline to midpoint and endpoint in response to the ONS intervention. The study population is Type 2 Diabetes (T2D) participants (n=30) who will ingest an Oral Nutritional Supplement (ONS) .

Read the detailed description

This is a single-arm interventional clinical study, the primary objective is to assess the changes in the small intestinal (SI) metagenomic profile of in diabetic participants from baseline to midpoint and endpoint in response to the ONS intervention. The study population is Type 2 Diabetes (T2D) participants (n=30) who will ingest an Oral Nutritional Supplement (ONS) specifically formulated for T2D participants (Glucerna®). While widely used, and despite a strong scientific rationale for their potential influence on the gut microbiota, the impact of nutritional supplements such as Glucerna® has not yet been tested on the gut microbiome. Understanding their impact on the microbiome can lead to new ways for ONS products to better support metabolic health, and long term glucose sugar control. Given the critical role of the small intestine in T2D, the study utilizes the SIMBA capsule to measure novel changes in the small intestine along with traditional measurements from fecal, saliva and blood.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • oral nutritional supplement
  • microbiome
  • small intestine
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 40-65 years old at the inclusion of the study, both female and male subjects.
  2. Has type 2 diabetes as evidenced by their medical history charts and is able to maintain number of medications, type and dose throughout the duration of the study.
  3. Has ≥ 6.5% and ≤ 9.5% based on a blood sample collected at the Screening Visit, documented within the past month or referred by a medical doctor.
  4. Normal to overweight ( 20-29.9).
  5. Weight is stable (has maintained current body weight within 3 kg) for the two months prior to the Baseline Visit.
  6. Is taking a maximum of 3 oral anti-diabetic drugs, one of which must be Metformin. Other class of medications permitted include: Sulfonylurea, SGLT2 inhibitors, and DPP4 inhibitors.
  7. Either a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to the Baseline Visit.
  8. Willingness to follow the protocol as described, including consumption of study product per the protocol and completing any forms/questionnaires needed throughout the study.
  9. The participant is willing to refrain from taking non-study diabetes-specific oral nutritional formulas over the entire course of the study.
  10. Willing to maintain their diet and physical activity levels during the study.
  11. Able to swallow a 25mm length and 9mm width sized capsule.
  12. At least a four-week between the completion of a previous research study that required ingestion of any study food or drug and their start in the current study. Signed ; willing and able to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  1. Confirmed type 1 diabetes and/or had a history of diabetic ketoacidosis.
  2. Use of exogenous insulin or GLP1 agonists for glucose control.
  3. Using diabetes-specific oral nutritional supplements(s), (e.g. Glucerna®, Boost etc.) defined as more than one eating occasion per week within the past 4 weeks (those users who can stop using such products for ≥4 weeks before baseline visit need not be excluded).
  4. Follows a non-typical eating pattern such as very low carbohydrate diet (e.g., Adkins diet, ketogenic diet, high protein diet).
  5. Has eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures in the opinion of the investigators.
  6. Galactosemia and lactose intolerance
  7. A chronic disease which in the opinion of the investigator, would adversely affect study safety or outcome. Such as, but not limited to

    • A significant cardiovascular event within 6 months prior to study entry or history of congestive heart failure, per physician evaluation.
    • End-stage organ failure (such as end-stage renal disease) or is post-organ transplant.
    • Current or history of renal disease or on dialysis or severe gastroparesis.
    • Current diagnosed hepatic disease such as liver cirrhosis or late-stage liver fibrosis. Participants with prevalent angina will not be excluded.
  8. A chronic, contagious, infectious disease, such as active tuberculosis, , or .
  9. Subject has current active malignant disease or was treated within the last 6 months for cancer, except basal or squamous cell skin carcinoma, prior to enrollment.
  10. Taking any herbals, dietary supplements, or medications during the past four weeks prior to baseline visit that could profoundly affect (in the opinion of the principal investigator or site physician) blood glucose, body weight, muscle, metabolism, appetite or microbiome (e.g. orlistat, contrave) (naltrexone/bupropion), Qsymia (phentermine/topiramate), Belviq (lorcaserin), incretin mimetics, other drugs indicated for weight loss, cannabis, , prebiotics and probiotic supplements). Those users who have stopped using such supplements/ medications for ≥4 weeks prior to baseline need not be excluded).
  11. Use of any medications in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, GLP-1 analogues); laxative use is allowed if it is kept unchanged in the week prior to the SIMBA capsule ingestion timepoints. Proton pump inhibitors (PPIs) are allowed provided a of 48 hours is respected before swallowing the SIMBA capsules and PPI treatment is resumed only 4 hours thereafter.

    - If willing prokinetic use can be discontinued for the study duration, with a washout period of 2 weeks

  12. Antibiotic use (except for topical use) ≤ 12 weeks prior to screening. Potential participants may be eligible once a 12-week washout is completed.
  13. Current infection (requiring medication and antibiotics), inpatient surgery or received systemic corticosteroid treatment [except for inhaled (includes nasal), topical, and ophthalmic steroids] in the last 3 months.
  14. Prior gastrointestinal disease, surgery, or radiation treatment which, in the Investigator's opinion, would interfere with consumption or digestion or absorption of study product, lead to intestinal structuring or obstruction with a risk of capsule non-excretion, including, e.g., achalasia, eosinophilic esophagitis, cancer diagnosis or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable.

    - Diagnosed with Crohn's disease, ulcerative colitis or celiac disease.

  15. History of known structural gastrointestinal abnormalities such as structures or fistulas leading to mechanical obstruction.
  16. Organic motility disorder, including gastroparesis, intestinal pseudo-obstruction, systemic sclerosis, Ogilvie's syndrome.
  17. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration.
  18. History of less than three (3) bowel movements per week. 13) Consumption of probiotic or prebiotic capsule supplements within 1 month prior to screening. Potential participants may be eligible once a 1-month washout is completed.
  19. Any prior Fecal Microbiota Transplantation.
  20. Colon cleanses/bowel prep for 2 weeks.
  21. Clotting or bleeding disorders (the use of Plavix® or a similar anticoagulant drug with no reported difficulty during blood draws will be allowed as per physician's opinion).
  22. Has blood or blood-related diseases (e.g. hemophilia, thalassemia, sickle cell disease, hereditary spherocytosis, glucose-6-phosphate dehydrogenase deficiency).
  23. Received a blood transfusion within the last 3 weeks.
  24. Allergic or intolerant to any ingredient found in the study products.
  25. Habitually engages in strenuous exercise (e.g., high intensity aerobic exercise, including heavy physical labor), duration of 1 hour or longer, 3 or more times per week. Potential participants may be eligible to participate if their levels exercise are reduced.
  26. Participant is actively enrolled in a weight loss program.
  27. Are scheduled for an MRI at any time during the study. Potential participants may be eligible to participate once their MRI procedure is completed.
  28. Pregnant or breastfeeding.
  29. Planning to become pregnant.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Interventional Arm

    Ingestion of the ONS

    Dietary Supplement: Oral nutritional supplement

Interventions

  • Dietary supplementOral nutritional supplement

    Consumption of the oral nutritional supplement

06

What researchers measure

Primary outcomes

  1. Primary Outcome

    To assess changes in small intestinal metagenomic profile in Type 2 diabetic participants from baseline to midpoint and endpoint in response to the ONS intervention, as measured using the SIMBA capsule.

    Time frame: Compared at intervention from baseline, midpoint, to endpoint (completion), an average of 6 weeks

Secondary outcomes

  1. Secondary 1

    Assess the change in metagenomic profile between the blood, saliva, and stool, of Type 2 diabetic participants in response response to the ONS intervention from baseline, to midpoint and endpoint using the SIMBA capsule.

    Time frame: Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

  2. Secondary 2

    Assess the change in metabolomic profile in the saliva blood, stool, and SI of Type 2 diabetic participants in response to the ONS intervention from baseline, to midpoint and endpoint using the SIMBA capsule.

    Time frame: Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

  3. Secondary 3

    Assess the microbial composition (superimposability of PLS-DA mapping) of the SI from samples collected by the SIMBA capsule

    Time frame: Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

  4. Secondary 4

    To assess changes in self-reported satiety in response to the ONS which will be measured at three timepoints: baseline, midpoint, and endpoint.

    Time frame: Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

  5. Secondary 5

    Identify potential metagenomic and metabolomic biomarkers that could predict or correlate with the response to the ONS intervention.

    Time frame: Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

  6. Secondary 6

    Assess the impact of the ONS intervention on gut function and overall gastrointestinal health, potentially using additional indicators such as gut permeability or inflammatory markers.

    Time frame: Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

07

Study locations

1 site
  • Nimble Science
    Calgary, Alberta T2L 1Y8, Canada
    • Gwen PhD Duytschaever, PhD · Contactclinical@nimblesci.com · 8664934633
    • Richdeep Gill, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Aug 2026, 11 months later.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 11 months is above that.

Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 25, 2024
StartEst.
Sep 2025
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06704022
Lead sponsor
Nimble Science Ltd.
Collaborators
Alberta Obesity Centre
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Sep 2025 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Aug 11, 2025

Study contacts

Gwen Duytschaever, PhD
Contact
clinical@nimblesci.com
8664934633
Isaac Wong, MBT
Contact
clinical@nimblesci.com
8664934633

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion